This week on Pharmacy Times, there are a number of important topics that will be covered and posted throughout the week, including:
- A video interview with Hannah Fish, PharmD, National Community Pharmacists Association’s Associate Director of Strategic Initiatives, on the next phase of the COVID-19 vaccination rollout following the FDA updating the Pfizer-BioNTech COVID-19 Vaccine EUA to be expanded to include children ages 12 and older.
- An overview of xevinapant, an early-stage antagonist of inhibitors of apoptosis proteins (IAPs), and its potential to help a large range of patients with cancer due to its enhancement effect in combination with chemoradiotherapy (CRT). Research shows that IAPs regulate a wide range of cellular processes that help tumor cells to survive and spread, from inhibition of apoptosis to regulation of cell proliferation and migration, and modulation of immune and inflammatory responses. As such, IAP antagonism represents a unique alternative mechanism of action to fight cancer, which can serve as a complement to immunotherapy and a booster of the antitumor effects of CRT.